A5100339963- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Virus-based gene therapy research
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Histone Deacetylase Inhibitors Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Cancer-related molecular mechanisms research
- ATP Synthase and ATPases Research
- Receptor Mechanisms and Signaling
- PARP inhibition in cancer therapy
- RNA modifications and cancer
- RNA Research and Splicing
- Quinazolinone synthesis and applications
- CRISPR and Genetic Engineering
- Cancer Mechanisms and Therapy
- interferon and immune responses
- Renal and related cancers
- Advanced biosensing and bioanalysis techniques
State Key Laboratory of Chemobiosensing and Chemometrics
2023
Hunan University
2023
UNSW Sydney
2014-2021
Cancer Institute of New South Wales
2014-2021
Children's Cancer Institute Australia
2013-2019
Sydney Children's Hospital
2014-2016
University of Bologna
2014
Garvan Institute of Medical Research
2014
Histone chaperone FACT acts in a positive feedback loop with MYCN and is therapeutic target neuroblastoma.
MYCN regulates polyamines in neuroblastoma, and combined inhibition of polyamine synthesis transport has therapeutic effects mouse models.
Background Patients with neuroblastoma due to the amplification of a 130-kb genomic DNA region containing MYCN oncogene have poor prognoses.
Abstract Myc transcriptional activity is frequently deregulated in human cancers, but a Myc-driven gene signature with prognostic ability across multiple tumor types remains lacking. Here, we selected 18 Myc-regulated genes from published studies of family targets epithelial ovarian cancer (EOC) and neuroblastoma. A score derived the was correlated to MYC/MYCN/MYCL1 expression panel 35 cell lines. The this evaluated neuroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), EOC...
Patients with neuroblastoma due to N-Myc oncogene amplification have a high frequency of tumor metastasis. However, it is not clear how induces cell migration, invasion and The histone demethylase JMJD1A activates gene transcription by demethylating the lysine 9 residue H3 (H3K9) at target promoters. long noncoding RNA MALAT1 lung cancer migration plays pivotal role in Here we demonstrated that up-regulated expression oncogene-amplified human cells directly binding promoter. Affymetrix...
Neuroblastoma is the most common solid tumor during early childhood. One of key features neuroblastoma extensive tumor-driven angiogenesis due to hypoxia. However, mechanism through which cells drive poorly understood. Here we show that long noncoding RNA MALAT1 was upregulated in human cell lines under hypoxic conditions. Conditioned media from transfected with small interfering RNAs (siRNA) targeting MALAT1, compared conditioned control siRNAs, induced significantly less endothelial...
MYCN gene amplification in neuroblastoma drives a expression program that correlates strongly with aggressive disease. Mechanistically, trimethylation of histone H3 lysine 4 (H3K4) at target promoters is strict prerequisite for this transcriptional to be enacted. WDR5 H3K4 presenter has been found have an essential role trimethylation. For reason, study, we investigated the relationship between WDR5-mediated and N-Myc programs cells. upregulated Gene analysis revealed genes included those...
Neuroblastoma is a pediatric cancer of the sympathetic nervous system where MYCN amplification key indicator poor prognosis. However, mechanisms by which promotes neuroblastoma tumorigenesis are not fully understood. In this study, we analyzed global miRNA and mRNA expression profiles tissues at different stages from TH-MYCN transgenic mice, model MYCN-driven neuroblastoma. On basis Bayesian learning network in compared pretumor ganglia TH-MYCN+/+ mice to age-matched wild-type controls,...
Abstract The RNA-binding protein dyskerin, encoded by the DKC1 gene, functions as a core component of telomerase holoenzyme well ribonuclear complexes involved in RNA processing and ribosome biogenesis. diverse roles dyskerin across many facets biology implicate its potential contribution to malignancy. In this study, we examined expression function neuroblastoma. We show that mRNA levels were elevated relative normal cells panel 15 neuroblastoma cell lines, where both N-Myc c-Myc directly...
Transcription factors (TFs) and microRNAs (miRNAs) are primary metazoan gene regulators. Regulatory mechanisms of the two main regulators great interest to biologists may provide insights into causes diseases. However, interplay between miRNAs TFs in a regulatory network still remains unearthed. Currently, it is very difficult study that involve both biological lab. Even at data level, involving miRNAs, genes will be too complicated achieve. Previous research has been mostly directed...
High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration neuroblastoma skin squamous carcinoma cells. However, role TRIM16 in melanoma is currently unknown. protein levels were markedly reduced human lines, compared with normal epidermal melanocytes due both DNA methylation stability. knockdown strongly increased melanocytes, while overexpression proliferation cells an interferon beta 1 (IFNβ1)-dependent manner. Chromatin...
MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced protein stability key component oncogenesis and maintained by multiple feedforward expression loops involving transactivation target genes. Here, we reveal oncogenic role novel binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that occupies PA2G4 gene promoter, stimulating transcription. Direct to blocked...
// Jeyran Shahbazi 1,2 , Christopher J. Scarlett 3,4 Murray D. Norris 1 Bing Liu Michelle Haber Andrew E. Tee Alice Carrier 5 V. Biankin 4,6 Wendy B. London 7 Glenn M. Marshall 1,8 Richard Lock and Tao 1,9 Children's Cancer Institute Australia for Medical Research, Sydney, 2 School of Biotechnology Biomolecular Sciences, UNSW Science, University New South Wales, 3 Environmental Life Newcastle, Ourimbah, 4 Research Program, Garvan INSERM, U1068, CRCM 'Stress cellulaire', Marseille F-13009,...
Amplification of the MYCN oncogene, a member MYC family transcriptional regulators, is one most powerful prognostic markers identified for poor outcome in neuroblastoma, common extracranial solid cancer childhood. While has been established as key driver malignancy underlying molecular mechanisms are poorly understood. Transcription factor activating enhancer binding protein-4 (TFAP4) reported to be direct target MYC. We show first time that high expression TFAP4 primary neuroblastoma...
// Pei Y. Liu 1, * , Nicholas Sokolowski Su T. Guo 2, Faraz Siddiqi 1 Bernard Atmadibrata Thomas J. Telfer 3 Yuting Sun Lihong Zhang 4 Denise Yu Joshua Mccarroll Bing Rui H. Yang 5 Xiang Andrew E. Tee Ken Itoh 6 Jenny Wang 7 Maria Kavallaris Michelle Haber Murray D. Norris Belamy B. Cheung Jennifer A. Byrne 8 David S. Ziegler 9 Glenn M. Marshall Marcel Dinger 10, 11 Rachel Codd Xu Tao Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, 2 School...
Survival rates for pediatric patients suffering from mixed lineage leukemia (MLL)-rearranged remain below 50% and more targeted, less toxic therapies are urgently needed. A screening method optimized to discover cytotoxic compounds selective MLL-rearranged identified CCI-006 as a novel inhibitor of CALM-AF10 translocated leukemias that share common leukemogenic pathways. inhibited mitochondrial respiration induced membrane depolarization apoptosis in subset (7/11, 64%) cell lines within few...
Histone deacetylase (HDAC) inhibitors are effective in MYCN-driven cancers, because of a unique need for HDAC recruitment by the MYCN oncogenic signal. However, much more combination with other anti-cancer agents. To identify novel compounds which act synergistically inhibitor, such as suberanoyl hydroxamic acid (SAHA), we performed cell-based, high-throughput drug screen 10,560 small molecule from drug-like diversity library and identified compound (SE486-11) enhanced cytotoxic effects...
Abstract Retinoids are an important component of neuroblastoma therapy at the stage minimal residual disease, yet 40–50% patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic (SAHA), is a potent inhibitor histone deacetylase (HDAC) classes I & II and has antitumor activity in vitro vivo. Fenretinide (4‐HPR) synthetic which acts on cancer cells through both nuclear receptor...
There is an urgent need for the development of less toxic, more selective and targeted therapies infants with leukemia characterized by translocation mixed lineage (MLL) gene. In this study, we performed a cell-based small molecule library screen on infant MLL-rearranged (MLL-r) cell line, PER-485, in order to identify inhibitors MLL-r leukemia. After screening initial hits cytotoxic effect against panel 30 lines including MLL wild-type (MLL-wt) leukemia, solid tumours control cells, CCI-007...